Welcome to our dedicated page for Erasca news (Ticker: ERAS), a resource for investors and traders seeking the latest updates and insights on Erasca stock.
Erasca, Inc. (Nasdaq: ERAS) is a clinical-stage precision oncology company dedicated to discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Their mission, embodied in their name, is to 'erase cancer'. The company's innovative approach aims to not just treat but potentially cure cancer by targeting and shutting down the RAS/MAPK pathway, which plays a crucial role in many types of cancer.
Erasca’s robust clinical pipeline includes promising drug candidates such as Naporafenib, a pan-RAF inhibitor with first-in-class potential targeting NRASm melanoma and RAS Q61X tissue agnostic solid tumors. The company's other notable candidates include ERAS-007, a highly selective oral ERK1/2 inhibitor, and ERAS-601, an oral SHP2 inhibitor, which target different nodes of the RAS/MAPK pathway. These efforts are supported by recent collaborations with industry giants like Novartis, who are providing crucial compounds like trametinib (MEKINIST®) for combination trials.
On the financial front, Erasca is well-funded with significant investments from both new and existing investors, having recently raised approximately $45 million in a private placement expected to close in April 2024. As of December 2023, the company reported $322 million in cash, cash equivalents, and marketable securities, ensuring a solid runway into the second half of 2026.
Among their latest achievements, Erasca has received FDA Fast Track Designation (FTD) for Naporafenib in combination with trametinib for advanced NRASm melanoma. This designation facilitates accelerated development and review processes, reflecting the potential of their therapies to address unmet medical needs.
The company’s pivotal Phase 3 SEACRAFT-2 trial for Naporafenib in post-immunotherapy settings for NRASm melanoma is slated to begin in the first half of 2024. Additionally, Erasca has announced exciting new partnerships and pipeline enhancements, including in-licensing two preclinical RAS programs, ERAS-0015 and ERAS-4001, to further solidify their leadership in the precision oncology space.
For more up-to-date information on Erasca, Inc., including their latest financial results and key upcoming milestones, visit their official website or recent press releases.
Erasca, a clinical-stage precision oncology company focused on RAS/MAPK pathway-driven cancers, announced the pricing of an underwritten offering of 86,486,486 shares of its common stock at $1.85 per share.
The offering is expected to raise approximately $160 million before underwriting discounts and expenses. Erasca has also granted underwriters a 30-day option to purchase an additional 12,972,972 shares.
The offering is anticipated to close on May 21, 2024, subject to customary closing conditions. J.P. Morgan and BofA Securities are the joint book-running managers.
Proceeds will fund research and development, as well as general corporate purposes. The offering is made under a shelf registration statement effective August 18, 2022.
Erasca, Inc. (Nasdaq: ERAS) reported strong Q1 2024 results with promising survival data for naporafenib plus trametinib in patients with NRASm melanoma, leading to an oversubscribed $45 million financing. The company extended its cash runway into H2 2026 and expects upcoming data readouts across multiple clinical programs. R&D and corporate highlights showcase continued progress and collaborations, positioning Erasca well for future growth.
Erasca, Inc. (Nasdaq: ERAS) will be presenting at the Bank of America Health Care Conference in Las Vegas, Nevada. The company focuses on developing therapies for RAS/MAPK pathway-driven cancers. The presentation will take place on May 15, 2024, at 4:20 pm Pacific Time.
FAQ
What is the current stock price of Erasca (ERAS)?
What is the market cap of Erasca (ERAS)?
What is Erasca, Inc.'s primary focus?
What are the key drugs in Erasca’s pipeline?
What recent achievements has Erasca reported?
How is Erasca funded?
What partnerships has Erasca entered into?
What is the SEACRAFT-2 trial?
What does FDA Fast Track Designation mean for Erasca?
What financial milestones has Erasca achieved recently?
What is the significance of Erasca's mission statement?
How does Erasca's technology target cancer?
